Fig. 3: FITC CAR T cells infiltrate into tumours and expand in the presence of amph-FITC.
From: Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
a, Schematic and timeline of therapy in B16F10 tumours, including CAR T booster vaccine. Created with Biorender.com. b,c, Localization of FLuc+ E2-m28z FITC CAR T cells in B16F10 tumour-bearing mice on day 8 (b) and quantification of whole mouse (top) and tumour (bottom) radiance (c) (n = 5 animals per group, biological replicates). White dashed circle indicates ___location of flank tumour. d, Representative immunohistochemistry on CT-2A tumours treated with i.t. amph-FITC ± amph-FITC vaccine, staining for CD8, at day 12 post-adoptive transfer. Scale bar, 50 µm. e, Quantification of CD8+ T cells per mm2 per field of view (FOV) in 10 FOV per tumour, n = 10 FOVs per condition. Replicates are technical replicates to capture T cell infiltration across many FOVs within the tumour. P values were determined by one-way ANOVA with Tukey’s post hoc test. Error bars represent standard error of the mean (c) and s.d. (e). NS, not significant; ****P < 0.0001.
